Biotech Values

[bxjwn9ru]

My understanding, based on prior discussions with Dew, is that Roche had an HCV exclusivity deal with ITMN and therefore could not just walk away from the partnership with ITMN if Roche ever wanted to license an outside HCV compound. I.e., Roche had to pay ITMN to terminate its HCV exclusivity deal with ITMN in order to have the freedom to license an HCV compound from another company.

Maybe ACH-1625 is on Roches radar. You never know. :)